Education
About Us
Working with TipRanks
Follow Us
InspireMD Inc (NSPR)
:NSPR
NSPR Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.81 - $3.80
Previous CloseN/A
Volume8.46K
Average Volume (3M)68.49K
Market Cap
$72.77M
Enterprise Value$90.46M
Total Cash (Recent Filing)$9.38M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.03
Next Earnings
May 20, 2025EPS Estimate
-0.2Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.84
Shares Outstanding26,083,763
10 Day Avg. Volume64,323
30 Day Avg. Volume68,492
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)10.67
Price to Cash Flow (P/CF)-3.20
P/FCF Ratio0.00
Enterprise Value/Market Cap1.24
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit50.06
Enterprise Value/Ebitda-3.05
Forecast
1Y Price Target
$5.00Price Target Upside77.94% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
---
InspireMD News
PremiumCompany Announcements
InspireMD Inc. Reports 2024 Financial Results and Strategic Progress
PremiumCompany Announcements
InspireMD’s Earnings Call: Cautious Optimism Amid Challenges
---
Bulls Say, Bears Say
Bulls Say
Acquisition ProspectsInspireMD could be an attractive add-on for Boston Scientific or other big MedTech cardiovascular players, including Medtronic, Abbott, or J&J.
FDA ApprovalInspireMD is approaching its most important catalyst, FDA approval of its CGuard carotid artery stent.
Market PotentialInspireMD can quickly build a $50M CGuard business and a $25M SwitchGuard business by 2028.
Bears Say
---
Ownership Overview
29.35% Insiders
0.07% Mutual Funds
12.78% Other Institutional Investors
57.81% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
NSPR FAQ
What was InspireMD Inc’s price range in the past 12 months?
InspireMD Inc lowest stock price was $1.81 and its highest was $3.80 in the past 12 months.
What is InspireMD Inc’s market cap?
InspireMD Inc’s market cap is $72.77M.
When is InspireMD Inc’s upcoming earnings report date?
InspireMD Inc’s upcoming earnings report date is May 20, 2025 which is in 67 days.
How were InspireMD Inc’s earnings last quarter?
InspireMD Inc released its earnings results on Mar 12, 2025. The company reported -$0.19 earnings per share for the quarter, beating the consensus estimate of -$0.195 by $0.005.
Is InspireMD Inc overvalued?
According to Wall Street analysts InspireMD Inc’s price is currently Undervalued.
Does InspireMD Inc pay dividends?
InspireMD Inc does not currently pay dividends.
What is InspireMD Inc’s EPS estimate?
InspireMD Inc’s EPS estimate is -0.2.
How many shares outstanding does InspireMD Inc have?
InspireMD Inc has 26,083,763 shares outstanding.
What happened to InspireMD Inc’s price movement after its last earnings report?
InspireMD Inc reported an EPS of -$0.19 in its last earnings report, beating expectations of -$0.195. Following the earnings report the stock price went up 0.717%.
Which hedge fund is a major shareholder of InspireMD Inc?
Currently, no hedge funds are holding shares in NSPR
---
InspireMD Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$5.00 (77.94% Upside)
$5.00 (77.94% Upside)
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
14.22%
12-Months-Change
Fundamentals
Return on Equity
-66.75%
Trailing 12-Months
Asset Growth
0.92%
Trailing 12-Months
Company Description
InspireMD Inc
InspireMD, Inc. is a medical device company, which engages in the development and commercialization of the stent platform technology for the treatment of complex vascular and coronary disease. Its products are marketed for use mainly in patients with acute coronary syndromes, notably acute myocardial infarction and saphenous vein graft coronary interventions. The company was founded in 2005 and is headquartered in Tel Aviv, Israel.
---
NSPR Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a mixed picture with strong revenue growth and clinical trial success for CGuard products, alongside anticipated US market expansion. However, increased operating expenses, decreased gross profit margins, and a higher net loss create financial challenges. The sentiment reflects cautious optimism with significant expectations from the US market entry.Read More>---
NSPR Stock 12 Month Forecast
Average Price Target
$5.00
▲(77.94% Upside)
Technical Analysis
Best Analysts Covering NSPR
1 Year
1 Year Success Rate
2/3 ratings generated profit
1 Year Average Return
+11.73%
assigned a buy rating 6 months ago
Copying Adam Maeder's trades and holding each position for 1 Year would result in 66.67% of your transactions generating a profit, with an average return of +11.73% per trade.
---